We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Low Cost Method Examines Single Leukemic Cells

By LabMedica International staff writers
Posted on 28 Oct 2016
Leukemia is a disease in which each cell can exhibit different genetic traits, and a cheap way has been developed to examine the individual cells and this breakthrough could transform leukemia treatment.

Cells are packed with genetic information that can be used to improve treatment of diseases such as cancer, but the ribonucleic acid (RNA) sequencing methods typically used today have one limitation in that they do not identify in which cells the genetic activity is taking place.

Scientists at the KTH Royal Institute of Technology (Stockholm, Sweden) and their colleagues developed a new method they used to examine individual tumor cells in patients with chronic lymphocytic leukemia (CLL), an important advance considering the team found the leukemia tumors to be comprised of cells with entirely different gene expressions. More...
They used cryopreserved peripheral blood mononuclear samples derived from three CLL patients. All cases were diagnosed and classified according to recently revised iwCLL criteria44 with a typical CLL immunophenotype.

Individual cells were sorted on a specially made glass surface and using analysis of RNA molecules with next-generation sequencing, from which one can tell which genes are active. The spatial information on the glass surface tells which cell a specific RNA molecule is to be found in. The FACS sorter utilized for analyses and single-cell sorting was a BD Influx. Images of sorted and stained cells on barcoded microarrays were recorded using a Metafer Vslide scanning system installed on an Axio Imager Z2 LSM700 microscope.

The method enabled massive microarray-based barcoding of expression patterns in single cells, termed MASC-seq. This technology enabled both imaging and high-throughput single-cell analysis, characterizing thousands of single-cell transcriptomes per day at a low cost of USD 0.13/cell, which is two orders of magnitude less than commercially available systems. The novel approach provides data in a rapid and simple way. Therefore, MASC-seq has the potential to accelerate the study of subtle clonal dynamics and help provide critical insights into disease development and other biological processes.

Joakim Lundeberg, PhD, a professor of Gene Technology and senior author of the study, said, “We found that CLL cells do not consist of a single cell type, but of a number of sub-clones that exhibit entirely different gene expression. With this new, highly cost-effective technology, we can now get a whole new view of this complexity within the blood cancer sample. Molecular resolution of single cells is likely to become a more widely-used therapy option.” The study was published on October 14, 2016, in the journal Nature Communications.

Related Links:
KTH Royal Institute of Technology


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit
New
Epstein-Barr Virus Test
Mononucleosis Rapid Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: Schematic diagram of multimodal single-cell MSI using tapping-mode scanning probe electrospray ionization (Photo courtesy of Yoichi Otsuka)

New Technology Improves Understanding of Complex Biological Samples

Tissues are composed of a complex mixture of various cell types, which complicates our understanding of their biological roles and the study of diseases. Now, a multi-institutional team of researchers... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.